Clinical Trial Update: A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 pediatric trial assessing safety, tolerability, and pharmacokinetics of apremilast (CC-10004) in moderate-to-severe plaque psoriasis; study completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2018-09-27